WildDISCO: Visualizing Whole Bodies in Unprecedented Detail
mehr
Storys zum Thema Genetik
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Potentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
mehr- 2
CARAMBA: New Hope for Multiple Myeloma Patients
mehr New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrArtilysin® - A Groundbreaking "Green Pharma" Solution
mehr- 2
Study Reveals Influence of Urban Environment on Mental Health
mehr First Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrAmicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
mehrBjörn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehr- 3
Sysmex Europe distributes MammaTyper®, an advanced breast cancer diagnostic assay, through the European distribution agreement with Cerca Biotech
mehr Technische Universität München
Genetically encoded nano-barcodes
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
mehrGenialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrMiltenyi Biotec acquires biosensor company lino Biotech
Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrEBiSC presents a new offering of iPSC-derived neurons
mehrType 1 Diabetes Awareness Campaign - K1DS ARE HEROES - started
mehrSwiss Start-Up “Mirai Foods” produces first cultivated tender steak / Breakthrough for Cultivated Premium Beef Steaks
Zurich (ots) - - Three patents for key technologies in “cultivated meat” - Food producer Angst AG takes stake in company - Innovative bioreactor improves efficiency and reduces costs A real new meat experience without sacrifice: Swiss start-up Mirai Foods achieves technological breakthrough for the cultivation ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehrVectorBuilder vann första pris i stor innovationstävling
Chicago, IL (ots) - --News Direct-- VectorBuilder Inc. - en global ledare inom genleveransteknik - meddelade att deras FoU- och tillverkningscenter i Guangzhou vann mästerskapet i sjunde globala tävlingen i innovation och företagande, som hölls i "Chuangke" Hangzhou, Kina. Denna inflytelserika och mycket konkurrensdrivna tävling är en av de största i Kina och täcker företag i tillväxtstadiet inom alla ...
mehrTechnische Universität München
Why are overweight people more susceptible to illness?
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22778 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/news-and-events/all-news/press-releases/details/warum-bekommen-uebergewichtige-menschen-haeufiger-erkrankungen Picture: https://mediatum.ub.tum.de/1612044 NEWS RELEASE Why are overweight people more susceptible to illness? Size of fat cells can cause ...
mehrVectorBuilder Won First Prize in Major Innovation Competition
Chicago, IL (ots) - --News Direct-- VectorBuilder Inc. – a global leader in gene delivery technologies – announced that its R&D and manufacturing center in Guangzhou won championship in the 7th “Chuangke Innovation and Entrepreneurship Global Competition” held in Hangzhou, China. This influential and highly competitive contest is one of the largest in China, covering growth-stage enterprises across all high-tech ...
mehrTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrFlu tests from R-Biopharm also detect new virus variants
mehrTechnische Universität München
Molecular monitoring of RNA regulation
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/news-and-events/all-news/press-releases/details/molecular-monitoring-of-rna-regulation Pictures: https://mediatum.ub.tum.de/1691366 NEWS RELEASE Molecular monitoring of RNA regulation New biological tool for tracking cellular processes The better we ...
mehr
Vorherige1234567Nächste